REG - Ergomed plc - Change of Nominated Adviser <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

19/08/2016 11:19

RNS Number : 1225H
Ergomed plc
15 August 2016
PRESS RELEASE
FOR IMMEDIATE RELEASE
Ergomed Plc
Change of Nominated Adviser
London, UK - 15 August 2016: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that it has appointed Numis Securities Limited ("Numis") as its Nominated Adviser with immediate effect. Stifel Nicolaus Europe Limited remain joint-broker to the Company alongside Numis. 
-ENDS -
Enquiries:
Ergomed Plc
Miroslav Reljanovic (Chief Executive Officer)
Stephen Stamp (Chief Financial Officer)
Tel: +44 (0) 1483 503205


Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser) 
James Black (Joint Broker)
Tel: +44 (0) 20 7260 1000


Stifel Nicolaus Europe Limited
Jonathan Senior (Joint Broker)
Tel: +44 (0) 20 7710 7600


FTI Consulting
Simon Conway / Mo Noonan / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
APPGGUGCRUPQPUC